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Key Points 
Question  Does neratinib plus paclitaxel improve progression-free survival compared with trastuzumab 
plus paclitaxel as first-line therapy in recurrent and/or metastatic ERBB2-positive breast cancer? 
Findings  In this randomized clinical trial that included 479 women, median progression-free survival 
was 12.9 months with neratinib-paclitaxel and 12.9 months with trastuzumab-paclitaxel with no 
statistically significant difference between groups. The incidence of central nervous system (CNS) 
recurrences was significantly lower and time to CNS metastases significantly delayed with neratinib-
paclitaxel. 
Meaning  Neratinib-paclitaxel is not superior to trastuzumab-paclitaxel in terms of progression-free 
survival in previously untreated women with ERBB2-positive metastatic breast cancer, and the CNS 
findings warrant further clinical investigation. 
Abstract 
Importance  Efficacious ERBB2 (formerly HER2 or HER2/neu)-directed treatments, in addition to 
trastuzumab and lapatinib, are needed. 
Objective  To determine whether neratinib, an irreversible pan-ERBB tyrosine kinase inhibitor, plus 
paclitaxel improves progression-free survival compared with trastuzumab plus paclitaxel in the first-line 
treatment of recurrent and/or metastatic ERBB2-positive breast cancer. 
Design, Setting, and Participants  In the randomized, controlled, open-label NEfERT-T trial conducted 
from August 2009 to December 2014 at 188 centers in 34 countries in Europe, Asia, Africa, and North 
America, 479 women with previously untreated recurrent and/or metastatic ERBB2-positive breast 
cancer were randomized to 1 of 2 treatment arms (neratinib-paclitaxel [n = 242] or trastuzumab-
paclitaxel [n = 237]). Women with asymptomatic central nervous system metastases were eligible, and 
randomization was stratified by prior trastuzumab and lapatinib exposure, hormone-receptor status, 
and region. 
Interventions  Women received neratinib (240 mg/d orally) or trastuzumab (4 mg/kg then 2 mg/kg 
weekly), each combined with paclitaxel (80 mg/m2 on days 1, 8, and 15 every 28 days). Primary 
prophylaxis for diarrhea was not mandatory. 
Main Outcome and Measures  The primary outcome was progression-free survival. Secondary end 
points were response rate, clinical benefit rate, duration of response, frequency, and time to 
symptomatic and/or progressive central nervous system lesions, and safety. 
Results  The intent-to-treat population comprised 479 women 18 years or older (neratinib-paclitaxel, 
n = 242; trastuzumab-paclitaxel, n = 237) randomized and stratified in their respective treatment arms 
by prior trastuzumab and lapatinib exposure, hormone-receptor status, and region. Median progression-
free survival was 12.9 months (95% CI, 11.1-14.9) with neratinib-paclitaxel and 12.9 months (95% CI, 
11.1-14.8) with trastuzumab-paclitaxel (hazard ratio [HR], 1.02; 95% CI, 0.81-1.27; P =.89). With 
neratinib-paclitaxel, the incidence of central nervous system recurrences was lower (relative risk, 0.48; 
95% CI, 0.29-0.79; P = .002) and time to central nervo 
us system metastases delayed (HR, 0.45; 95% CI, 0.26-0.78; P = .004). Common grade 3 to 4 adverse 
events were diarrhea (73 of 240 patients [30.4%] with neratinib-paclitaxel and 9 of 234 patients [3.8%] 
with trastuzumab-paclitaxel), neutropenia (31 patients [12.9%] vs 34 patients [14.5%]) and leukopenia 
(19 patients [7.9%] vs 25 patients [10.7%]); no grade 4 diarrhea was observed. 
Conclusions and Relevance  In first-line ERBB2-positive metastatic breast cancer, neratinib-paclitaxel 
was not superior to trastuzumab-paclitaxel in terms of progression-free survival. In spite of similar 
overall efficacy, neratinib-paclitaxel may delay the onset and reduce the frequency of central nervous 
system progression, a finding that requires a larger study to confirm. 
 
